The Forgotten Crisis: Critical Illness in Sickle Cell Adults

Dr Neeraj Manikath , claude.ai

Abstract

Background: Sickle cell disease (SCD) affects millions globally, yet critical illness in adults remains underrecognized and inadequately managed. This review addresses key management strategies, focusing on exchange transfusion thresholds, hepatic sequestration, and emerging complement inhibitor therapies.

Objectives: To provide evidence-based guidance for intensivists managing adult SCD patients, highlighting recent advances in therapeutic approaches and diagnostic pearls.

Methods: Comprehensive literature review of peer-reviewed articles, clinical guidelines, and emerging therapies through January 2025.

Results: Critical SCD complications require prompt recognition and aggressive management. Exchange transfusion remains cornerstone therapy with evolving threshold criteria. Hepatic sequestration represents a life-threatening emergency often misdiagnosed. Complement inhibitors show promise in multiorgan failure scenarios.

Conclusions: Improved understanding of SCD pathophysiology and novel therapeutic approaches can significantly improve outcomes in critically ill adults with SCD.

Keywords: Sickle cell disease, critical care, exchange transfusion, hepatic sequestration, complement inhibitors, multiorgan failure

Introduction

Sickle cell disease affects approximately 100,000 Americans and millions worldwide, with the majority surviving into adulthood due to improved childhood care.¹ However, adult SCD patients face unique challenges in critical care settings, where delayed recognition and suboptimal management contribute to excess morbidity and mortality. The transition from pediatric to adult care often results in fragmented healthcare delivery, leaving intensivists ill-equipped to manage these complex patients.²

Critical illness in SCD adults presents distinct pathophysiological challenges. Unlike pediatric presentations dominated by pain crises and acute chest syndrome, adults develop progressive organ dysfunction, particularly affecting pulmonary, renal, and hepatic systems.³ The interplay between chronic hemolysis, endothelial dysfunction, and acute inflammatory responses creates a perfect storm for multiorgan failure.

This review addresses three critical areas often overlooked in adult SCD management: optimal exchange transfusion strategies, recognition and treatment of hepatic sequestration, and the emerging role of complement inhibition in multiorgan failure.

Pathophysiology of Critical Illness in SCD

The Vicious Cycle of Vaso-occlusion

SCD pathophysiology extends beyond simple mechanical obstruction by sickled cells. The disease represents a complex inflammatory vasculopathy involving multiple interconnected pathways:

Hemolysis-induced endothelial dysfunction occurs through free hemoglobin scavenging of nitric oxide, leading to vasoconstriction and reduced vascular reactivity.⁴ Simultaneously, free heme activates toll-like receptor 4, triggering inflammatory cascades that promote further vaso-occlusion.

Complement activation plays an increasingly recognized role in SCD pathophysiology. Chronic hemolysis activates the alternative complement pathway, with C5a and membrane attack complex formation contributing to endothelial injury and microvascular thrombosis.⁵

Adhesion molecule upregulation creates a proinflammatory endothelial phenotype. Increased expression of VCAM-1, ICAM-1, and P-selectin facilitates leukocyte-endothelial interactions, promoting vaso-occlusion and organ dysfunction.⁶

Critical Care Pearl: The "Sickling Threshold"

Unlike common belief, sickling occurs not just with hypoxia but also with dehydration, acidosis, fever, and stress. Maintain SpO₂ >95%, adequate hydration, and strict temperature control. Even "mild" hypoxia (88-92%) can trigger cascading vaso-occlusion in susceptible patients.

Exchange Transfusion: Redefining Thresholds and Timing

Traditional Approach vs. Modern Evidence

Historically, exchange transfusion decisions relied on HbS levels >30% or clinical severity scores. Recent evidence suggests this approach may be inadequate for critically ill adults, where earlier intervention yields superior outcomes.⁷

Evidence-Based Thresholds for Exchange Transfusion

Acute Chest Syndrome (ACS):

Immediate exchange: PaO₂/FiO₂ ratio <200, bilateral infiltrates, or requirement for mechanical ventilation
Urgent exchange: Single lobe involvement with declining oxygenation despite optimal medical therapy
Target: HbS <30%, Hgb 9-11 g/dL⁸

Acute Stroke:

Emergent exchange: Any acute neurological deficit with imaging confirmation
Target: HbS <15% within 4 hours, maintain <30% for minimum 30 days
Monitoring: Transcranial Doppler velocities if available⁹

Multiorgan Failure:

Threshold: Two or more organ systems with evidence of vaso-occlusion
Target: HbS <20%, considering patient's baseline hemoglobin
Duration: Continue until organ function stabilizes¹⁰

Critical Care Hack: The "Golden Hour" Concept

In severe vaso-occlusive crises with organ dysfunction, the first hour determines outcome. If exchange transfusion is indicated, initiate within 60 minutes of decision. Delays beyond 2 hours significantly increase mortality risk.

Automated vs. Manual Exchange Protocols

Automated Exchange (Preferred):

More precise HbS reduction
Better volume control in fluid-sensitive patients
Reduced procedure time and nursing requirements
Lower risk of hemodynamic instability¹¹

Manual Exchange Protocol: When automated exchange unavailable, use the following approach:

Calculate blood volume: 70 mL/kg (men), 65 mL/kg (women)
Exchange 1.5-2 blood volumes over 4-6 hours
Monitor HbS every 250-500 mL exchanged
Maintain isovolemia with careful fluid balance

Oyster Alert: Delayed Hemolytic Transfusion Reactions

SCD patients have 25-30% risk of delayed hemolytic transfusion reactions, often occurring 7-14 days post-transfusion. Watch for: unexplained anemia, reticulocytosis, increased LDH, and new alloantibodies. This can precipitate hyperhemolysis syndrome, requiring immunosuppression rather than additional transfusions.¹²

Hepatic Sequestration: The Great Mimicker

Pathophysiology and Clinical Presentation

Hepatic sequestration represents acute trapping of sickled cells within hepatic sinusoids, leading to rapid hepatomegaly, anemia, and potential liver failure. Unlike pediatric presentations, adult hepatic sequestration often presents insidiously, mimicking other hepatic emergencies.¹³

Clinical Triad:

Rapid hepatomegaly (>2 cm increase from baseline)
Acute anemia (>2 g/dL drop from baseline)
Evidence of hemolysis (elevated LDH, indirect bilirubin)

Diagnostic Challenges in Adults

Adult hepatic sequestration frequently masquerades as:

Acute hepatitis: Elevated ALT/AST with hepatomegaly
Choledocholithiasis: RUQ pain with hyperbilirubinemia
Budd-Chiari syndrome: Hepatomegaly with ascites
Heart failure: Hepatomegaly with elevated JVP¹⁴

Diagnostic Pearl: The "Reverse Hemoglobin-Bilirubin Dissociation"

In hepatic sequestration, hemoglobin drops faster than expected for the degree of hemolysis. Calculate the hemolysis index: (Total bilirubin - Direct bilirubin) × 20. If hemoglobin drop exceeds this calculation, suspect sequestration.

Management Strategies

Immediate Assessment:

Hemoglobin, reticulocyte count, LDH, bilirubin fractionation
Liver function tests including PT/INR
Hepatic ultrasound with Doppler (rule out vascular occlusion)
Blood type and crossmatch for transfusion

Therapeutic Approach:

Mild Sequestration (Hgb >7 g/dL, stable vitals):

Simple transfusion to hemoglobin 9-10 g/dL
Avoid over-transfusion (risk of hyperviscosity)
Close monitoring for progression¹⁵

Severe Sequestration (Hgb <7 g/dL or hemodynamic instability):

Immediate exchange transfusion
Target HbS <30%, hemoglobin 9-10 g/dL
Consider partial exchange if simple transfusion initiated

Critical Care Hack: The "Hepatic Handshake" Sign Palpate the liver edge while monitoring central venous pressure. In hepatic sequestration, liver edge becomes increasingly prominent with inspiration (positive hepatic-jugular reflux), unlike other causes of hepatomegaly where this relationship is absent or minimal.

Complications and Monitoring

Hepatic Failure Indicators:

INR >1.5 with clinical bleeding
Encephalopathy (often subtle in SCD patients)
Worsening synthetic function (albumin, cholinesterase)

Management of Hepatic Failure:

N-acetylcysteine 150 mg/kg loading dose, then 50 mg/kg q4h
Fresh frozen plasma for coagulopathy with bleeding
Consider early hepatology consultation for potential transplant evaluation¹⁶

Complement Inhibitors: A Novel Therapeutic Frontier

Rationale for Complement Inhibition

Recent research has identified complement activation as a central mediator of SCD pathophysiology. The alternative complement pathway remains constitutively activated in SCD patients, with evidence of terminal complement complex deposition in multiple organs during crisis.¹⁷

Ravulizumab in SCD: Emerging Evidence

Ravulizumab, a long-acting C5 complement inhibitor, represents a paradigm shift in SCD management. Unlike eculizumab, ravulizumab's extended half-life allows for 8-weekly dosing, improving patient compliance and steady-state coverage.¹⁸

Mechanism of Action:

Inhibits C5 cleavage, preventing C5a and C5b-9 formation
Reduces complement-mediated hemolysis
Decreases endothelial activation and adhesion molecule expression
Attenuates inflammatory cascade propagation¹⁹

Clinical Applications in Critical Care

Multiorgan Failure Syndrome: Emerging case series suggest benefit in SCD patients with multiorgan failure, particularly when combined with exchange transfusion. The proposed mechanism involves:

Reduced complement-mediated endothelial injury
Decreased inflammatory cytokine release
Improved microvascular perfusion²⁰

Dosing Protocol for Critical Care:

Loading dose: 2700 mg IV over 35 minutes
Maintenance: 3000 mg at day 15, then every 8 weeks
Adjust for body weight >100 kg (3300 mg loading, 3600 mg maintenance)

Critical Care Pearl: Meningococcal Prophylaxis

All patients receiving complement inhibitors require meningococcal vaccination (if not contraindicated) and antibiotic prophylaxis. Use penicillin V 250 mg BID or azithromycin 250 mg daily for penicillin-allergic patients. Continue throughout therapy.

Monitoring and Safety Considerations

Pre-treatment Requirements:

Meningococcal vaccination (types A, C, W, Y, and B) minimum 2 weeks prior
Screen for active infections
Baseline complement levels (CH50, C3, C4)

Ongoing Monitoring:

Weekly CBC with differential
Liver function tests
Signs of meningococcal infection
Hemolysis markers (LDH, haptoglobin, indirect bilirubin)²¹

Oyster Alert: Breakthrough Hemolysis

Approximately 10-15% of patients on complement inhibitors experience breakthrough hemolysis due to C5 variants with reduced binding affinity. Monitor for unexplained anemia, elevated LDH, and decreased haptoglobin. May require dose escalation or alternative complement targeting.

Multiorgan Failure in SCD: An Integrated Approach

Recognition and Early Intervention

Multiorgan failure in SCD differs from typical ICU presentations. The onset is often insidious, with patients appearing deceptively stable until rapid decompensation occurs.

Early Warning Signs:

Acute kidney injury with bland urinalysis
Unexplained metabolic acidosis
Rapid hemoglobin decline without obvious bleeding
New oxygen requirement in previously stable patient²²

Critical Care Hack: The "SCD SOFA" Score

Modify traditional SOFA scoring for SCD patients:

Respiratory: Consider baseline oxygen requirement
Renal: Adjust for chronic kidney disease baseline
Hepatic: Include hemolysis markers in assessment
Neurologic: Consider silent strokes in baseline assessment

Therapeutic Bundle for Multiorgan Failure

Hour 0-1:

Aggressive hydration (avoid overload in renal dysfunction)
Oxygen therapy (target SpO₂ >95%)
Exchange transfusion preparation
Complement inhibitor consideration

Hour 1-6:

Exchange transfusion if indicated
Organ-specific support measures
Infectious workup and empiric antibiotics
Pain management optimization

Hour 6-24:

Reassess organ function
Consider complement inhibitor if multiorgan failure persists
Continuous monitoring of hemolysis markers
Early mobility and rehabilitation planning²³

Special Considerations in Critical Care Management

Anesthesia and Procedural Considerations

Pre-procedural Optimization:

Hemoglobin >9 g/dL (consider transfusion if <8 g/dL)
Adequate hydration status
Temperature maintenance >36.5°C
Oxygen saturation >95%²⁴

Intraoperative Management:

Avoid hypothermia (forced air warming)
Maintain normocapnia
Liberal oxygenation strategy
Regional anesthesia when possible

Pain Management in the ICU

Multimodal Approach:

Continue home opioid regimen (avoid withdrawal)
Add adjuvant medications (gabapentin, ketamine)
Consider patient-controlled analgesia
Regional techniques when appropriate²⁵

Oyster Alert: Opioid Tolerance vs. Addiction SCD patients often require high opioid doses due to tolerance, not addiction. Avoid stigmatization and under-treatment. Use validated pain scales and treat to patient-reported comfort, not predetermined dose limits.

Fluid Management Pearls

Hydration Strategy:

Target urine output 1-2 mL/kg/hour
Avoid excessive fluid in heart/kidney failure
Use isotonic crystalloids (avoid hypotonic solutions)
Monitor for signs of volume overload²⁶

Infection Prevention and Management

SCD patients have functional asplenia, increasing infection risk. Implement enhanced surveillance:

Daily blood cultures for fever >38°C
Low threshold for empiric antibiotics
Consider atypical organisms (Salmonella, Pneumococcus)
Maintain vaccination status²⁷

Future Directions and Emerging Therapies

Gene Therapy Advances

Recent FDA approvals of gene therapies (Casgevy, Lyfgenia) may reduce future ICU admissions, but critically ill patients require immediate interventions. Current gene therapy recipients may still experience complications during the immediate post-treatment period.²⁸

Novel Complement Targets

Beyond C5 inhibition, research focuses on:

Factor D inhibitors (upstream complement blockade)
C3 inhibitors (broader complement suppression)
Properdin inhibitors (alternative pathway specific)²⁹

Artificial Intelligence Applications

Machine learning algorithms show promise in:

Predicting vaso-occlusive crises
Optimizing transfusion timing
Identifying early multiorgan failure
Personalizing pain management protocols³⁰

Conclusions and Clinical Recommendations

Critical illness in adult SCD patients represents a complex challenge requiring specialized knowledge and aggressive intervention. Key takeaways for practicing intensivists include:

Early Recognition: Maintain high index of suspicion for SCD complications, particularly in African American patients with unexplained multiorgan dysfunction.
Exchange Transfusion: Lower thresholds and earlier intervention improve outcomes. Aim for HbS <30% in most critical situations, <20% in multiorgan failure.
Hepatic Sequestration: Often mimics other hepatic emergencies. Look for rapid hepatomegaly with disproportionate anemia relative to hemolysis markers.
Complement Inhibition: Consider ravulizumab in multiorgan failure scenarios, particularly when traditional therapies prove insufficient.
Holistic Approach: Address pain management, infection prevention, and psychosocial needs alongside acute medical interventions.

The management of critically ill SCD adults requires a paradigm shift from reactive to proactive care. By implementing evidence-based protocols and embracing novel therapeutic approaches, intensivists can significantly improve outcomes for this vulnerable population.

References

Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381(9861):142-151.
Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010;303(13):1288-1294.
Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-895.
Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12):1383-1389.
Merle NS, Grunenwald A, Rajaratnam H, et al. Complement activation during intravascular hemolysis: implication for sickle cell disease. Blood. 2019;133(5):466-479.
Belcher JD, Chen C, Nguyen J, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014;123(3):377-390.
Sarode R, Ballas SK, Garcia A, et al. Red blood cell exchange: 2015 American Society for Apheresis guideline. J Clin Apher. 2017;32(4):203-213.
Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342(25):1855-1865.
Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5-11.
Swerdlow P. Red cell exchange in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2006:48-53.
Kim HC. Red cell exchange: special focus on sickle cell disease. Hematology Am Soc Hematol Educ Program. 2014;2014(1):450-456.
Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion. 2002;42(1):37-43.
Ahn H, Li CS, Wang W. Sickle cell hepatopathy: clinical presentation, treatment, and outcome in pediatric and adult patients. Pediatr Blood Cancer. 2005;45(2):184-190.
Bauer TW, Moore GW, Hutchins GM. The liver in sickle cell disease. A clinicopathologic study of 70 patients. Am J Med. 1980;69(6):833-837.
Hatton CS, Bunch C, Weatherall DJ. Hepatic sequestration in sickle cell anaemia. Br Med J (Clin Res Ed). 1985;290(6469):744-745.
Banerjee S, Owen C, Chopra S. Sickle cell hepatopathy. Hepatology. 2001;33(5):1021-1028.
Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014;124(19):2930-2936.
Kulasekararaj AG, Hill A, Szer J, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540-549.
Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol. 2014;32:433-459.
Camous L, Roumenina L, Bigot S, et al. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood. 2011;117(4):1340-1349.
Peffault de Latour R, Fremeaux-Bacchi V, Porcher R, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015;125(5):775-783.
Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4 Suppl):S512-521.
Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033-1048.
Firth PG, Head CA. Sickle cell disease and anesthesia. Anesthesiology. 2004;101(3):766-785.
Brandow AM, Brousseau DC, Pajewski NM, Panepinto JA. Vaso-occlusive painful events in sickle cell disease: impact on child well-being. Pediatr Blood Cancer. 2010;54(1):92-97.
Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317-1322.
Davies SC, Luce PJ, Win AA, Riordan JF, Brozovic M. Acute chest syndrome in sickle-cell disease. Lancet. 1982;1(8274):36-38.
Frangoul H, Altshuler D, Cappellini MD, et al. Exagamglogene autotemcel for sickle cell disease. N Engl J Med. 2021;384(3):252-260.
Risitano AM, Marotta S, Ricci P, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157.
Tanabe P, Hafner JW, Martinovich Z, Artz N. Adult emergency department patients with sickle cell pain crisis: a learning collaborative model to improve analgesic management. Acad Emerg Med. 2012;19(4):430-438.

Conflicts of Interest: The authors declare no conflicts of interest.

Funding: No specific funding was received for this work.

Thursday, July 24, 2025

Critical Illness in Sickle Cell Adults